Therapeutic Action
First line antituberculosis antibacterial (sterilising and bactericidal activity)
PDF page 267
Loading InternPractice…
Drug reference
First line antituberculosis antibacterial (sterilising and bactericidal activity)
PDF page 267
Tuberculosis, in combination with other antituberculosis antibacterials
PDF page 267
Do not administer to patients with hypersensitivity to pyrazinamide, severe hepatic impairment or severe gout. May cause: gout and arthralgias, hepatotoxicity, photosensitivity (limit sun exposure), rash, gastrointestinal disturbances, hypersensitivity reactions. Monitor liver function in patients with known hepatic disease. If signs of hepatotoxicity (e.g. jaundice) develop, pyrazinamide should be discontinued until symptoms resolve. Pregnancy: no contra-indication Breast-feeding: no contra-indication
PDF page 267
400 mg tablet 150 mg dispersible tablet
PDF page 267
Child under 30 kg: 35 mg/kg (30 to 40 mg/kg) once daily Child 30 kg and over and adult: 25 mg/kg (20 to 30 mg/kg) once daily Do not exceed 2 g daily. Patient with renal impairment: 25 mg/kg 3 times weekly
PDF page 267
According to protocol
PDF page 267
For patients on first-line antituberculosis treatment, pyrazinamide is given as part of a fixed dose combination.
PDF page 268
– – Below 25 °C
PDF page 268
35 mg/kg (30 to 40 mg/kg) once daily
PDF page 267
25 mg/kg (20 to 30 mg/kg) once daily
PDF page 267